1、 CHIENCM,YANGSH, YANG C C, et al.CardiotoxinIIIinducesc-junN-terminalkinase-dependentapoptosisin HL-60human leukaemia cells[J].Cell Bionchem Funct,2008,26(1): 111-118. CHIENCM,YANGSH, YANG C C, et al.CardiotoxinIIIinducesc-junN-terminalkinase-dependentapoptosisin HL-60human leukaemia cells[J].Cell Bionchem Funct,2008,26(1): 111-118.
2、HINMAN C L, TANG H P. A membrane lytic immunoconjugate selective for human tumor T lymphocytes [J]. Int J Immunopha, 1998(20): 467-468.HINMAN C L, TANG H P. A membrane lytic immunoconjugate selective for human tumor T lymphocytes [J]. Int J Immunopha, 1998(20): 467-468.
3、 WU M, MING W,TANG Y, et al. The anticancer effect of cytotoxin 1 from naja atra cantor venom is mediated by a lysosomal cell death pathway involving lysosomal membrane permeabilization and cathepsin B release[J].Am J Chin Med,2013,41(3):643-663. WU M, MING W,TANG Y, et al. The anticancer effect of cytotoxin 1 from naja atra cantor venom is mediated by a lysosomal cell death pathway involving lysosomal membrane permeabilization and cathepsin B release[J].Am J Chin Med,2013,41(3):643-663.
4、 雷丹青, 王秋雁, 刘绵林, 等. 广西眼镜蛇毒细胞毒素的分离及对人鼻咽癌等细胞抑制作用的研究[J].中国药理学通报, 2002(18): 61-64. 雷丹青, 王秋雁, 刘绵林, 等. 广西眼镜蛇毒细胞毒素的分离及对人鼻咽癌等细胞抑制作用的研究[J].中国药理学通报, 2002(18): 61-64.
5、 PINATO D J, GRAHAM J, GABRA H, et al. Evolving concepts in the management of drugresistant ovarian cancer: Dose dense chemotherapy and the reversal of clinical platinum resistance[J]. Cancer Treat Rev, 2013, 39(2): 153-160. PINATO D J, GRAHAM J, GABRA H, et al. Evolving concepts in the management of drugresistant ovarian cancer: Dose dense chemotherapy and the reversal of clinical platinum resistance[J]. Cancer Treat Rev, 2013, 39(2): 153-160.
6、BOGUSH T A, POPOVA A S, DUDKO E A, et al. ERCC1 as a marker of ovarian cancer resistanceto platinum drugs[J]. Antibiot Khimioter, 2015, 60(3-4): 42-50.BOGUSH T A, POPOVA A S, DUDKO E A, et al. ERCC1 as a marker of ovarian cancer resistanceto platinum drugs[J]. Antibiot Khimioter, 2015, 60(3-4): 42-50.
7、 COPUR M S, GAUCHAN D, RAMAEKERS R, et al. Neoadjuvant chemotherapy or primary debulking surgery for stage iiic ovarian cancer[J]. J Clin Oncol, 2017, 35(7):802-803. COPUR M S, GAUCHAN D, RAMAEKERS R, et al. Neoadjuvant chemotherapy or primary debulking surgery for stage iiic ovarian cancer[J]. J Clin Oncol, 2017, 35(7):802-803.
8、 吴敏燕, 孔天翰,唐娅,等. 舟山眼镜蛇细胞毒素1对K562细胞的抑制作用[J].中国病理生理杂志,2011, 27(7): 1297-1301. 吴敏燕, 孔天翰,唐娅,等. 舟山眼镜蛇细胞毒素1对K562细胞的抑制作用[J].中国病理生理杂志,2011, 27(7): 1297-1301.
9、 TSAI P C, CHU C L, CHIU C C, et al. Inhibition of Src activation with cardiotoxin III blocks migration and invasion of MDA-MB-231 cells[J].Toxicon, 2013,(74):56-67. TSAI P C, CHU C L, CHIU C C, et al. Inhibition of Src activation with cardiotoxin III blocks migration and invasion of MDA-MB-231 cells[J].Toxicon, 2013,(74):56-67.
10、 FEOFANOV A V, SHARONOV G V, ASTAPOVA M V, et al. Cancer cell injury by cytotoxins from cobravenom is mediated though lysosomal damage[J].Biochem J, 2005, 390(1):11-18. FEOFANOV A V, SHARONOV G V, ASTAPOVA M V, et al. Cancer cell injury by cytotoxins from cobravenom is mediated though lysosomal damage[J].Biochem J, 2005, 390(1):11-18.
11、 SAMUEL P, MULCAHY L A, FURLONG F, et al. Cisplatin induces the release of extracellular vesicles from ovarian cancer cells that can induce invasiveness and drug resistance in bystander cells[J].Philos Trans R Soc Lond B Biol Sci,2018,373(1737): 20170065. SAMUEL P, MULCAHY L A, FURLONG F, et al. Cisplatin induces the release of extracellular vesicles from ovarian cancer cells that can induce invasiveness and drug resistance in bystander cells[J].Philos Trans R Soc Lond B Biol Sci,2018,373(1737): 20170065.
12、 FERLAY J, SOERJOMATARAM I, DIKSHIT R, et al. Cancer incidence and mortality worldwide: sources, Methods and major patterns in GLOBOCAN 2012[J].Int J Cancer, 2015, 136(5): 359-386. FERLAY J, SOERJOMATARAM I, DIKSHIT R, et al. Cancer incidence and mortality worldwide: sources, Methods and major patterns in GLOBOCAN 2012[J].Int J Cancer, 2015, 136(5): 359-386.
13、 JAYSON G C, KOHN E C, KITCHENER H C, et al. Ovarian cancer[J]. Lancet,2014,384(9951):1376-1388. JAYSON G C, KOHN E C, KITCHENER H C, et al. Ovarian cancer[J]. Lancet,2014,384(9951):1376-1388.
14、 CHEN W, ZHENG R, BAADE P D, et al. Cancer statistics in China[J]. CA Cancer J Clin, 2016, 66(2): 115. CHEN W, ZHENG R, BAADE P D, et al. Cancer statistics in China[J]. CA Cancer J Clin, 2016, 66(2): 115.